Global TROP2 Antibody Market Clinical Trials Insight 2026 Report Findings:
• Research Methodology
• Global & Regional Market Analysis
• Global TROP2 Antibody Market Opportunity Assessment
• Market and Drug Sales Insight 2020 Till 2026
• Approved Drug In Market: 1 Drugs
• Future Market Assessment By Indication Till 2026
• Ongoing Clinical Trials Assessment by Status, Phase & Region
• Key Market Dynamics
• Competitor Landscape
Trophoblast cell surface antigen 2 (Trop-2) is a glycoprotein that spans the epithelial membrane surface and plays a role in cell self-renewal, proliferation, and transformation. In normal physiological condition, TROP2 plays critical in embryonic development, placental tissue formation, embryo implantation, stem cell proliferation, and organ development. Apart from this, a variety of human cancers including breast, lung, urothelial, gastric, colorectal, pancreatic, prostatic, cervical, head and neck, and ovarian carcinomas are also associated with high expression of Trop2. Therefore, targeting Trop2 emerged out to be of great interest to researchers for the management of several cancers.
Trodelvy (Sacituzumab Govitecan) is a first in class antibody drug conjugate and topoisomerase inhibitor conjugate directed to the Trop-2 receptor. The drug was developed by Gilead Sciences and was initially approved for the management of previously treated metastatic triple negative breast cancer. Later, the regulatory bodies expanded approval to drug for the treatment of first line treatment for triple negative breast cancer as well as metastatic urothelial cancer. Currently, Trodelvy does not faces any competition in the market as it is the only TROP2 inhibitor approved in the market. It’s been only one year since the entry of drug in the market and it has shown robust sales of US$ 380 Million in 2021.
The robust response of Trodelvy in the management of several cancers have surged the further research and development activities in global Trop2 targeted drugs market. For instance, Daiichi Sankyo has developed novel TROP2 antibody drug conjugate, datopotamab deruxtecan (Dato-DXd, DS-1062a), with a potent DNA topoisomerase I inhibitor (DXd). The recent clinical trial has demonstrated that the investigational drug has a manageable safety profile in treating patients with advanced or metastatic breast cancer, non–small cell lung cancer, and other tumor types. The entrance of novel TROP-2 inhibitor will increases the competition to already approved Trodelvy during the forecast period.
As cancer is a multifactorial disease, researchers believed that combinational therapy is the most successful strategy to enhance efficacy, increase response, reverse resistance and reduce toxicity as well as address tumor heterogeneity upon using different drugs of different dynamics and molecular targets. Recently in 2021, Gilead Sciences collaborated with Merck to evaluate Trodelvy in combination with Keytruda in patients with metastatic triple negative breast cancer. Apart from this, Daiichi Sankyo is also evaluating datopotamab deruxtecan in combination with Keytruda for non-small cell lung cancer. The coming years will see rapid approval of several combinational approaches utilizing Trop2 targeted drugs, which will further drive the growth of market.
Apart from antibody drug conjugate, researchers have also adopted several other approaches including bispecific antibody ad chimeric antigen receptor T cell therapy for targeting Trop2. Several Trop 2-targeting chimeric antigen receptor-T (CAR-T) cells have presented their activities against various epithelial tumor cell lines, such as breast, prostate and pancreatic tumor cells. In addition, researchers have also developed a bispecific antibody F7AK3 that recognizes both trophoblast cell surface antigen 2 (TROP2) and CD3 and evaluated its antitumor activities both in vitro and in vivo. However, these are present in early stages of clinical development and are expected to flourish in market during the forecast period.
As per report findings, the global TROP2 targeted drugs market will surpass US$ 4 Billion by 2024 which is mainly attributed to increase in geriatric population, subsequent rise in cancer, and high demand of targeted drugs in its management. The report provides insight into approved TROP2 targeted drug patent, price and sales insight 2020 till 2028. In addition, comprehensive analysis on ongoing clinical trials and key drugs in research and development is also mentioned in the report. The major companies mentioned in report include Immunomedics, Gilead Science, Klus Pharma, Biothera, Janux Theapy, Pfizer, and several others.